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Abstract: To investigate anticancer effect of lycopene, we examined the effects of lycopene 
on  the  oxidative  injury  and  immunity  activities  of  N-methyl-N′-nitro-N-nitrosoguanidine 
(MNNG)-induced gastric cancer rats. The animals were divided into five groups. Group I 
served as the normal control and was given corn oil orally for 20 weeks. Group II were 
induced  with  MNNG  200  mg/kg  body  weight  by  oral  gavage  at  days  0  and  14,  and 
saturated NaCl (1 mL per rats) was given once every three days for four weeks until the end 
of the experimental period. Group III, IV and V were posttreated with lycopene (50, 100 
and 150 mg/kg body weight, dissolved in corn oil) from the sixth week of MNNG (as in 
group II) induction up to the end of the experimental period. In the presence of MNNG, 
MDA and immunity levels were significantly increased, whereas enzymatic (SOD, CAT, 
and GPx) antioxidant activities were decreased in the treated rats compared with normal 
control  rats.  Administration  of  lycopene  to  gastric  carcinoma-induced  rats  largely  
up-regulated  the  redox  status  and  immunity  activities  to  decrease  the  risk  of  cancer 
compared to group II. We conclude that up-regulation of antioxidants and immunity by 
lycopene treatment might be responsible for the anticancer effect in gastric carcinoma. 
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1. Introduction 
During  the  past  five  decades,  the  incidence  and  mortality  rates  for  gastric  cancer  (GC)  have 
decreased worldwide, especially in developed countries [1]. Nevertheless, GC is still the second largest 
cause  of  cancer-related  death,  and  the  overall  outcome  for  patients  with  GC  has  not  improved 
significantly  over  recent  decades  [2].  N-Methyl-N′-nitro-nitrosoguanidine  (MNNG)  is  a  gastric 
carcinogen  in  several  animal  species  and  has  been  used  in  a  number  of  systems  to  dissect  the 
cocarcinogenic  potential  of  various  compounds  in  the  induction  of  gastric  adenocarcinoma.  The 
existence  of  the  mechanism  of  action  of  MNNG  is  thought  to  be  due  to  its  decomposition  to  
short-lived highly reactive electrophiles, of which the alkonium ion is probably the ultimate mutagen, 
and electrophilic attack on nucleophilic sites of DNA bases that leads to altered bases [3]. In addition, 
sodium chloride (NaCl) enhances  both  the initiation  and promotion stages of experimental gastric 
carcinogenesis in rats [4–6]. 
Reactive oxygen species-mediated tissue injury is a final common pathway for a myriad of disease 
processes [7,8]. The body is continuously exposed to free radicals and ROS, both from external sources 
(sunlight, other forms of radiation, pollution) and endogenously generated sources. Oxidative stress 
can cause cancer [9], and it has been reported that the gastrointestinal tract is thought to be, at the same 
time,  a  major  site  for  oxidant  production  and  also  a  source  of  antioxidants.  Oxidative  stress  can 
modulate the apoptotic program [10] and could lead to gastric cancer [11]. 
Effective  immunity  protects  against  pathogens,  enables  wound  healing  and  tissue  repair,  and 
defends against some types of tumors. Tumor cells can evade immune detection and elimination by 
various mechanisms [12]. When this occurs, robust immunity is still essential for maintaining the 
general health of the cancer patient. 
Phenolic compounds are widely present in plants and have recently received considerable attention 
due to their antioxidant and anti-inflammatory properties. Lycopene, a carotenoid mostly found in 
tomatoes and tomato products, is a powerful antioxidant with a singlet-oxygen-quenching capacity 47 
and 100 times greater than that of β-carotene and vitamin E respectively [13,14]. Lycopene is also a 
potent  neuroprotective  [15],  antiproliferative,  anticancer  [16–19],  anti-inflammatory,  cognition 
enhancer [20] and hypocholesterolemic agent [21–23]. 
In the present study, we report on the antioxidant and immunity activities of the lycopene in gastric 
cancer rats. 
2. Methods 
2.1. Extraction of Lycopene 
Fifty grams of fresh and finely ground tomato peels were placed into amber flasks, to which 500 mL 
of 0.05% (w/v) BHT in acetone, 500 mL of ethanol and 250 mL of hexane were rapidly added. The 
flasks were magnetically stirred for 15 min, after which time 400 mL of deionized water were poured 
into the flask to allow phase separation to occur. The flasks were stirred continuously for 5 min and 
then the system was left at room temperature for further 5 min. Finally, a sample of the upper hexane 
layer was taken and analyzed for lycopene content. The process was repeated three times and the total Int. J. Mol. Sci. 2011, 12                       
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lycopene content was calculated as the sum of the values obtained in each extraction stage. HPLC 
analysis showed that the purity of lycopene was 96%. 
2.2. Animals 
A total of 40, 6-week-old, male Wistar rats, were supplied by laboratory animal center of Zhejiang 
Chinese Medical University. The rats were raised in an air-conditioned room under controlled lighting 
(12 h lighting/day) and provided with food and water at discretion. Animal care and surgery protocols 
were approved by the Animal Care Committees of China. All animals were appropriately conducted 
and used in a scientifically valid and ethical manner. 
2.3. Experimental Design 
The rats received a standard diet (energy, 15.1591 kJ/kg; crude protein, 22.08%; crude fat, 4.10%; 
crude fiber, 3.15%; ash, 5.14%; sand silica, 1.13%) and were divided into 5 groups of 8 animals each. 
Group I served as the normal control and was given corn oil orally for 20 weeks. Group II were 
induced with MNNG 200 mg/kg body weight once daily by oral gavage for two weeks, and saturated 
NaCl (1 mL per rat) was then given once every 3 days for 4 weeks and then maintained until the end of 
the experimental period. Group III, IV and V were posttreated with lycopene (50, 100 and 150 mg/kg 
body weight, dissolved in corn oil) once daily from the sixth week of MNNG (as in group II) induction 
up to the end of the experimental period. The body weights were measured at the end of experiment. 
The experiment was terminated in the 21st week, and all rats were killed after an overnight fast. Blood 
was collected, and the plasma separated was used for analysis. The stomachs were excised to prepare a 
10% homogenate for biochemical measurements. Frozen gastric tissue was ground in liquid nitrogen 
and suspended in a homogenization buffer consisting of 50 mM Tris–HCl, pH 8.2, 1 mM EDTA,  
0.1%  Triton  X-100,  and  proteinase  inhibitor  cocktail  (Roche,  Mannheim,  Germany).  After 
centrifugation in a microcentrifuge at 4 C, the supernatants were used to determine enzyme activity and 
protein concentration. 
2.4. Biochemical Analysis 
2.4.1. SOD Activity Assay 
The SOD activity was spectrophotometrically measured using the method developed by Marklund 
and  Marklund  [24].  Briefly,  SOD  was  detected  on  the  basis  of  its  ability  to  inhibit  
superoxide-mediated  reduction.  One  unit  was  determined  as  the  amount  of  enzyme  that  inhibited 
oxidation of pyrogallol by 50%. The activity was expressed as U/mg protein. 
2.4.2. CAT Activity Assay 
Catalase (CAT) activity was measured according to the Aebi [25] method. One unit of CAT activity 
was defined as the amount of enzyme required to decompose 1 μmol of H2O2 in 1 min. In a cuvette 
containing 1.95 mL of a 50 mM phosphate buffer (pH 7.0), 0.05 mL of tissue supernatant was added. 
The reaction was started by the addition of 1.0 mL of freshly prepared 30 mM H2O2. The rate of Int. J. Mol. Sci. 2011, 12                       
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decomposition of H2O2 was measured spectrophotometrically at 240 nm for 1 min. Using the reaction 
time (Δt) of the absorbance (A1 and A2), the following equation was generated to calculate the rate 
constant (k): k = (2.3/Δt)(log A1/A2). The enzyme activity was expressed as k mg
−1 protein. 
2.4.3. Assay of Glutathione Peroxidase Activity 
Glutathione peroxidase (GPx) activity was measured by the procedure of Flohe and Gunzler [26].  
One milliliter of reaction mixture that contained 0.3 mL of phosphate buffer (0.1 M, pH 7.4), 0.2 mL 
of glutathione (GSH) (2 mM), 0.1 mL of sodium azide (10 mM), 0.1 mL of H2O2 (1 mM), and 0.3 mL 
of  stomach  supernatant  was  prepared.  After  incubation  at  37  ° C  for  15  min,  the  reaction  was 
terminated by addition of 0.5 mL 5% TCA. Tubes were centrifuged at 1500 g for 5 min and the 
supernatant was collected. 0.2 mL of phosphate buffer (0.1 M, pH 7.4), and 0.7 mL of 5,5’-dithio-bis-
(2-nitrobenzoic acid)(DTNB, 0.4 mg/mL) were added to 0.1 mL of reaction supernatant. After mixing, 
absorbance was recorded at 420 nm and the enzyme activity was calculated as U/mg protein. 
2.4.4. The Tissues MDA Concentration 
The tissues MDA concentration was determined using the method described by Jain et al. [27], 
based on TBA reactivity. Briefly, 0.2 mL supernatant obtained from tissues, 0.8 mL phosphate buffer 
(pH  7.4),  0.025  mL  BHT  and  0.5  mL  30%  TCA  were  added  to  the  tubes  and  mixed.  After  2  h 
incubation at −20 ° C, the mixture was centrifuged (4000 ×  g) for 15 min. After this, 1 mL supernatant 
was taken and added to each tube, and then 0.075 mL of 0.1 M EDTA and 0.25 mL of 1% TBA were 
added. These tubes with Teflon-lined screw caps were incubated at 90 ° C in a water bath for 15 min and 
cooled to room temperature. The optical density was measured at 532 for tissues MDA concentration. 
2.4.5. IL-2, IL-4, IL-6, IL-10, TNF-α, IgA, IgG and IgM Levels 
The  concentrations  of  interleukin-2  (IL-2),  interleukin-6  (IL-6),  interleukin-4  (IL-4),  and 
interleukin-10 (IL-10) in the supernatant were determined using appropriate commercial ELISA kits 
for  the  murine  form  of  these  cytokines.  ELISAs  were  performed  according  to  the  manufacturers’ 
recommendations. The intensity of each sample was read at 450nm in a microplate spectrophotometer. 
Plasma  tumor  necrosis  factor  alpha  (TNF-α)  level  was  determined  by  commercial  ELISA  kits 
according  to  the  protocol  recommended  by  the  manufactures.  The  results  were  expressed  as  the 
quantity per ml plasma. 
Blood IgA, IgM and IgG levels were measured with a commercially available ELISA kits. 
2.5. Statistical Analysis 
All  data  are  presented  as  means  ±   SD.  Statistical  analyses  were  done  using  SPSS  (Statistical 
Package for Social Science, SPSS Inc., Chicago, IL, USA) program, and significance of each group 
was verified with one-way ANOVA followed by Duncan’s test (p < 0.05). Int. J. Mol. Sci. 2011, 12                       
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3. Results 
In the normal group, the rats looked perfectly relaxed, moved quickly and ate well. Their hair looked 
bright, and faeces was hard and granular. In the MNNG-treated groups, the rats looked less lively or 
vigorous, moved slowly, ate less and had diarrhea. Their hair looked loose and lusterless. The body 
weights of rats in the model group were significantly lower than those in the normal control group. 
Pathological  examination  showed  that  MNNG-treated  rats  had  varying  degrees  of  atrophy  and 
dysplasia on histological examination of the gastric mucosa. These indicated that gastric cancer model 
had been successfully established (data not shown). 
There  was  no  marked  difference  in  body  weight  between  groups  before  experiment.  After 
experiment, the average body weight of the gastric cancer model rats was significantly (p < 0.05) 
reduced  compared  to  that  of  the  normal  control  rats.  Lycopene  treatment  significant  (p  <  0.05) 
increased the body weight of the gastric cancer rats (Table 1). 
Table 1. Effect of Lycopene treatment on body weight of gastric cancer rats. 
Group 
Body weight (g) 
Before experiment  After experiment 
I  187.5 ±  15.3  223.1 ±  19.4 
II  188.2 ±  17.8  202.3 ±  22.1
a 
III  185.2 ±  16.2  209.4 ±  18.6 
IV  184.8 ±  19.1  211.5 ±  23.5
c 
V  186.7 ±  19.3  218.2 ±  20.6
c 
Values are given as Mean ±  SD for groups of eight rats each. 
a p < 0.05, gastric cancer model rats 
(group II) were compared with normal control (group I); 
c p < 0.05, lycopene treated rats (group III, 
IV and V) were compared with gastric cancer model control (group II). 
Compared with the normal control rats, significantly (p < 0.01) increased MDA levels of blood and 
gastric tissues were observed in the gastric cancer model rats (Tables 2 and 3). The gastric cancer rats 
exhibited an increased MDA level at the end of the experiment; this state was significantly ameliorated 
by the lycopene treatment. The activities of SOD, CAT and GSH-Px in the blood and gastric tissue 
were significantly (p < 0.01) decreased by MNNG treatment in comparison with the normal control 
rats. Similarly, the administration of the lycopene significantly (p < 0.01) enhanced the activities of 
antioxidant enzymes in blood and gastric tissues of MNNG-treatment rats. 
Table 2. Effect of Lycopene treatment on blood SOD, CAT, GSH-Px activities and MDA 
level in gastric cancer rats. 
Group  SOD (U/mg)  CAT (U/mg)  GSH-Px (U/mg)  MDA (U/mg) 
I  182.16 ±  17.29  29.85 ±  2.17  31.63 ±  3.72  8.27 ±  0.69 
II  98.26 ±  7.27
b  16.72 ±  1.99
b  18.92 ±  2.41
b  12.18 ±  0.93
b 
III  126.13 ±  13.83
d  19.82 ±  1.68
d  23.86 ±  2.83
d  10.73 ±  0.82
c 
IV  162.95 ±  19.04
d  22.47 ±  3.01
d  27.91 ±  3.09
d  9.32 ±  0.79
d 
V  188.29 ±  20.11
d  28.14 ±  3.12
d  30.61 ±  3.21
d  8.05 ±  0.91
d 
Values are given as Mean ±  SD for groups of eight rats each. 
b p < 0.05, gastric cancer model rats 
(group II) were compared with normal control (group I); 
c p < 0.05, 
d p < 0.01, lycopene treated rats 
(group III, IV and V) were compared with gastric cancer model control (group II). Int. J. Mol. Sci. 2011, 12                       
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Table 3. Effect of Lycopene treatment on gastric SOD, CAT, GSH-Px activities and MDA 
level in gastric cancer rats. 
Group  SOD (U/mg)  CAT (U/mg)  GSH-Px (U/mg)  MDA (U/mg) 
I  200.14 ±  27.31  38.12 ±  4.42  27.29 ±  3.28  6.39 ±  0.72 
II  117.32 ±  14.21
b  21.72 ±  3.17
b  20.13 ±  2.41
b  9.31 ±  1.32
b 
III  152.71 ±  17.08
d  26.92 ±  3.05
d  23.81 ±  2.64
c  8.14 ±  0.93
c 
IV  170.48 ±  19.36
d  29.33 ±  3.14
d  26.18 ±  2.91
d  7.53 ±  0.84
d 
V  194.28 ±  22.13
d  37.11 ±  4.25
d  29.52 ±  3.28
d  6.54 ±  0.74
d 
Values are given as Mean ±  SD for groups of eight rats each. 
b p < 0.05, gastric cancer model rats 
(group II) were compared with normal control (group I); 
c p < 0.05, 
d p < 0.01, lycopene treated rats 
(group III, IV and V) were compared with gastric cancer model control (group II). 
One-way ANOVA showed an overall significant effect of drug treatment on blood IL-2, IL-4, IL-6, 
IL-10 and TNF-α levels (Table 4). Compared with the normal control rats, blood IL-2, IL-4, IL-10 and 
TNF-α levels were significantly reduced in the gastric cancer model rats, while blood IL-6 level was 
significantly  increased.  One-way  ANOVA  revealed  that  lycopene  treatment  significantly  enhanced 
blood IL-2, IL-4, IL-10, TNF-α levels and reduced IL-6 level in a dose-dependent manner. 
Compared with the normal control rats, significantly decreased blood IgG, IgA and IgM levels were 
observed in the gastric cancer model rats (Table 5). Pharmacological test showed that the treatment of 
animals with lycopene elevated blood IgG, IgA and IgM levels compared to gastric cancer model rats 
in a dose-dependent manner. 
Table 4. Effect of Lycopene treatment on blood IL-2, IL-4, IL-10, IL-6 and TNF-α levels in 
gastric cancer rats. 
Group  IL-2 (ng/mL)  IL-4 (ng/mL)  IL-10 (ng/mL)  IL-6 (ng/mL)  TNF-α ( ng/mL) 
I  6.04 ±  0.83  21.54 ±  1.83  90.91 ±  10.63  70.63 ±  8.42  4.13 ±  0.67 
II  4.83 ±  0.51
b  15.62 ±  1.72
b  62.76 ±  3.84
b  89.17 ±  9.59
b  2.69 ±  0.49
b 
III  5.42 ±  0.63
c  17.42 ±  2.08
c  74.93 ±  6.20
d  82.61 ±  10.07
c  3.08 ±  0.44
d 
IV  5.82 ±  0.62
d  18.96 ±  2.11
d  82.17 ±  5.81
d  78.49 ±  9.48
d  3.51 ±  0.51
d 
V  6.11 ±  0.73
d  20.51 ±  2.54
d  89.53 ±  5.39
d  75.37 ±  8.37
d  3.99 ±  0.53
d 
Values are given as Mean ±  SD for groups of eight rats each. 
b p < 0.05, gastric cancer model rats 
(group II) were compared with normal control (group I); 
c p < 0.05, 
d p < 0.01, lycopene treated rats 
(group III, IV and V) were compared with gastric cancer model control (group II). 
Table  5.  Effect  of  Lycopene  treatment  on  blood  IgG,  IgA  and  IgM  levels  in  gastric  
cancer rats. 
Group  IgG (g/L)  IgA (g/L)  IgM (g/L) 
I  5.03 ±  0.31  0.64 ±  0.05  0.71 ±  0.08 
II  3.52 ±  0.03
b  0.43 ±  0.04
b  0.55 ±  0.06
b 
III  3.97 ±  0.04
c  0.52 ±  0.06
c  0.62 ±  0.07
c 
IV  4.58 ±  0.05
d  0.59 ±  0.06
d  0.68 ±  0.05
d 
V  4.89 ±  0.06
d  0.63 ±  0.07
d  0.74 ±  0.06
d 
Values are given as Mean ±  SD for groups of eight rats each. 
b p < 0.05, gastric cancer model rats 
(group II) were compared with normal control (group I); 
c p < 0.05, 
d p < 0.01, lycopene treated rats 
(group III, IV and V) were compared with gastric cancer model control (group II). Int. J. Mol. Sci. 2011, 12                       
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4. Discussion 
Lycopene has been implicated as having a potentially beneficial impact in a number of chronic 
diseases  including  cancer.  Evidence  from  epidemiological  and  animal  studies  supports  a  potential 
chemopreventive role of lycopene [28–30]. Studies have shown the anti-cancer properties of lycopene 
against many cancer cells, including the cancer cells of the stomach [31], lung [32], and colon [19]. 
In this study, a significant decrease in average body weight was observed in the cancer-induced rats. 
The subsequent increase in body weight upon administration of lycopene could be because of the 
protective efficacy of the lycopene. Because weight loss in cancer patients results in a poor prognosis, 
body weight restoration upon lycopene administration suggests a potential therapeutic benefit. Free 
radicals do not really affect weight loss, but they do harm your overall health. If you’re not healthy, 
then weight loss is kind of a moot point. The substantial weight loss observed in cancer-bearing rats 
could be because of cancer cachexia, anorexia, or malabsorption [33], which reportedly contributes to 
progressive wasting, notably in skeletal muscle and adipose tissue. Lycopene may possess an excellent 
antitumor potential and antioxidant benefit, which might improve rats’ health and digestive function. 
Subsequently, the increase in food intake might have facilitated the rise in body weight. 
The detrimental effect of reactive oxygen species (ROS) has been examined in gastric tissue in 
detail; in addition to prostaglandin (PG) reduction, the increase in ROS levels is also important to the 
basic mechanism of gastric damage formation [34]. This state of oxidative stress can result in injury to 
all the important cellular components like proteins, DNA and membrane lipids which can cause cell 
death. Oxidants are capable of stimulating cell division, which is a critical factor in mutagenesis. When 
a cell with a damaged DNA strand divides, cell metabolism and duplication becomes deranged. Thus, a 
mutation  can  arise,  which  is  an  important  factor  in  carcinogenesis.  In  recent  years,  increasing 
experimental and clinical data has provided compelling evidence for the involvement of oxidative 
stress  in  large  number  of  pathological  states  including  carcinogenesis  [35,36].  It  is  believed  that 
antioxidants exert their protective effect by decreasing oxidative damage to DNA and by decreasing 
abnormal increases in cell division. Therefore, it is believed that the protective functions of antioxidant 
mechanisms play a role in the treatment of ulcers of the gastric mucosa [37]. Healthy tissue cells have 
many  mechanisms  that  can  prevent  the  detrimental  effects  of  ROS  or  can  repair  existing  
damage—primarily  enzymes,  and  secondarily,  glutathione,  melatonin  and  antioxidant  vitamins, 
prevent tissue damage by maintaining ROS at physiologic concentration in cells [38]. 
In this study, we evaluated the oxidant and antioxidant parameters of blood and gastric tissues in 
gastric cancer rats. Significantly increased MDA level and decreased antioxidant enzyme activities 
were detected in gastric cancer rats. This means that there may be a relation between gastric cancer and 
gastric oxidant and antioxidant parameters. The administration of lycopene at 100, 200 and 300 mg/kg 
doses decreased the level of oxidant parameters (MDA) and increased blood and gastric antioxidant 
parameters (SOD, CAT and GSH-Px) significantly. CAT, SOD and other antioxidants are endogenous 
factors that reduce toxic effects of ROS [39,40]. So, we can hypothesize that lycopene may reduce 
oxidative  injury  of  gastric  cancer  rats  partly  through  stimulating  antioxidant  enzyme  activities. 
Subsequently, it may alleviate gastric cancer symptoms. 
Many  gastric  cancer  patients  have  a  variable  degree  of  immunological  impairment,  including 
decreased cellular immunity [41,42]. Cytokines such as interferons, interleukin and tumor necrosis Int. J. Mol. Sci. 2011, 12                       
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factor have been widely tested in the treatment of cancer. Interleukin-2 (IL-2) or aldesleukin is used to 
treat skin melanomas and kidney cancer. IL-4 has been shown to have a modest but direct inhibitory 
effect on the growth of tumor cells of hematopoietic and nonhematopoietic origin in vitro and in vivo, 
including those derived from human melanoma, non-Hodgkin’s malignant B-lymphoma, and colon, 
renal, gastric, and breast carcinoma [43–47]. IL-6 is an interleukin that acts as both a pro-inflammatory 
and  anti-inflammatory  cytokine.  It  is  secreted  by  T  cells  and  macrophages  to  stimulate  immune 
response  to  trauma,  especially  burns  or  other  tissue  damage  leading  to  inflammation. 
Advanced/metastatic cancer patients have higher levels of IL-6 in their blood [48]. Hence, there is an 
interest  in  developing  anti-IL-6  agents  as  therapy  against  many  of  these  diseases  [49,50].  
Interleukin-10 (IL-10) is a small protein known as a cytokine that functions as an important regulator 
of the immune system. Although IL-10 is known to have many different roles in the immune system, 
its two major activities include inhibition of cytokine production by macrophages and inhibition of the 
accessory functions of macrophages during T cell activation [51]. The effects of these actions cause  
IL-10  to  play  an  anti-inflammatory  role  in  the  immune  system.  TNF-α  contributes  to  several 
pathophysiological  states  initiated  by  infectious  or  inflammatory  agents  by  producing  ROS  and 
inducing pro-inflammatory chemoattractant cytokine cascades. A regulatory role of TNF-α in epithelial 
cell repair has been described [52,53]. It is well established that TNF-α stimulates IL-8 and contributes 
to epithelial cell injury and apoptosis [54–56]. In this study, blood IL-2, IL-4, IL-10 and TNF-α levels 
in gastric cancer model control rats were significantly lower than those in normal control rats. Blood 
IL-6 level in gastric cancer model control rats was markedly higher than that in normal control rats. 
This indicated that immunity function had decreased in gastric cancer rats. Lycopene treatment had 
significantly increased blood IL-2, IL-4, IL-10, TNF-α levels and reduced the IL-6 level in gastric 
cancer rats. In addition, Lycopene treatment could still enhance blood IgA, IgG and IgM levels in 
gastric cancer rats. These results suggest that Lycopene treatment could improve immunity function in 
gastric cancer rats. 
5. Conclusion 
The overall results of this study indicate that lycopene represents a potential source of plant drugs. 
At this stage of our study, we can deduce that lycopene appears to be worthy of consideration as an 
antioxidant, immune and antitumor medicine.  
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